Celgene

Roche’s Tecentriq gets fast review in triple negative breast cancer
Roche’s Tecentriq gets fast review in triple negative breast cancer
Pharmaforum
Roche
Genentech
Tecentriq
Celgene
Abraxane
FDA
triple negative breast cancer
Flag link:
Bristol-Myers Squibb snags quick Empliciti combo nod in multiple myeloma
Bristol-Myers Squibb snags quick Empliciti combo nod in multiple myeloma
Fierce Pharma
Bristol-Myers Squibb
AbbVie
Empliciti
FDA
Multiple Myeloma
Celgene
Pomalyst
Flag link:
Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma
Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma
Fierce Pharma
Celgene
Revlimid
Roche
Rituxan
follicular lymphoma
Flag link:
Celgene to launch five new products through to 2020
Celgene to launch five new products through to 2020
PM Live
Celgene
Revlimid
FDA
fedratinib
ozanimod
luspatercept
bb2121
liso-cel
Flag link:
Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
earnings
biotech
Biogen
Alexion Pharmaceuticals
Bristol-Myers Squibb
Celgene
Gilead Sciences
Merck
Biomarin
Galapagos
Seattle Genetics
Dr Reddy's
Flag link:
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
CP Wire
Celgene
ozanimod
multiple sclerosis
Flag link:
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
Celgene
ozanimod
multiple sclerosis
Flag link:
Celgene notches positive Otezla data in scalp psoriasis as it guns for market expansion
Celgene notches positive Otezla data in scalp psoriasis as it guns for market expansion
Fierce Pharma
Celgene
Otezla
scalp psoriasis
FDA
Flag link:
Drumbeat of bad news continues at OncoMed as Celgene dumps option on one of its last pipeline efforts
Drumbeat of bad news continues at OncoMed as Celgene dumps option on one of its last pipeline efforts
Endpoints
OncoMed
Celgene
navicixizumab
Flag link:
Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory
Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory
Motley Fool
Bluebird Bio
Amgen
Celgene
AMG-420
bb2121
Flag link:
Celgene's CEO Wants to Make the Biotech's Best-Selling Drug Obsolete
Celgene's CEO Wants to Make the Biotech's Best-Selling Drug Obsolete
Motley Fool
Revlimid
Celgene
Pharma CEOs
Mark Alles
Flag link:
The reinvention of Bob Hugin: Amid anger over drug prices, a former pharma CEO makes a run for the Senate
The reinvention of Bob Hugin: Amid anger over drug prices, a former pharma CEO makes a run for the Senate
Stat
Bob Hugin
Celgene
Pharma CEOs
Senate
politics
Flag link:
Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review
Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review
Yahoo/Zacks.com
Bristol-Myers Squibb
Empliciti
Celgene
Pomalyst
Multiple Myeloma
Flag link:
Can Celgene’s Most Important Drugs Keep Growing?
Can Celgene’s Most Important Drugs Keep Growing?
Motley Fool
Celgene
Multiple Myeloma
Flag link:
Celgene (CELG) Beats on Q2 Earnings, Ups View
Celgene (CELG) Beats on Q2 Earnings, Ups View
Marketwatch
Celgene
earnings
Flag link:
BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China
BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China
CP Wire
BeiGene
Celgene
tislelizumab
China
monoclonal antibodies
Flag link:
Can Celgene's latest Revlimid win reverse the company's bad-news streak?
Can Celgene's latest Revlimid win reverse the company's bad-news streak?
Fierce Pharma
Celgene
Revlimid
clinical trials
Roche
Rituxan
non-Hodgkin lymphoma
Flag link:
Number 7? Celgene partner BeiGene joins the crowd with stellar PD-1/L1 data from a pivotal test
Number 7? Celgene partner BeiGene joins the crowd with stellar PD-1/L1 data from a pivotal test
Endpoints
Celgene
BeiGene
tiselizumab
Hodgkin's lymphoma
Flag link:
7 companies to watch during Q2 earnings
7 companies to watch during Q2 earnings
Biopharma Dive
earnings
Biogen
Gilead Sciences
Amgen
Celgene
AbbVie
Pfizer
Spark Therapeutics
Flag link:
Novartis' MS patent win also a win for Celgene's impending MS drug: analyst
Novartis' MS patent win also a win for Celgene's impending MS drug: analyst
Medical Marketing and Media
Celgene
Novartis
ozanimod
Gilenya
MS
multiple sclerosis
patents
Flag link:

Pages